Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/20/2020 10/21/2020 10/22/2020 10/23/2020 10/26/2020 Date
60.55(c) 60.21(c) 60.67(c) 60.79(c) 59.865 Last
9 208 006 7 493 735 17 061 786 30 965 444 8 132 747 Volume
-0.03% -0.56% +0.76% +0.20% -1.52% Change
More quotes
Financials (USD)
Sales 2020 24 029 M - -
Net income 2020 2 246 M - -
Net Debt 2020 3 105 M - -
P/E ratio 2020 37,0x
Yield 2020 4,42%
Sales 2021 23 947 M - -
Net income 2021 7 285 M - -
Net Debt 2021 1 294 M - -
P/E ratio 2021 10,6x
Yield 2021 4,68%
Capitalization 76 214 M 76 214 M -
EV / Sales 2020 3,30x
EV / Sales 2021 3,24x
Nbr of Employees 11 800
Free-Float 99,6%
More Financials
Company
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.5%): especially royalties and... 
More about the company
Notations Surperformance© of Gilead Sciences, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about GILEAD SCIENCES, INC.
01:44pGILEAD SCIENCES : Completes Acquisition of Immunomedics, Inc.
AQ
01:44pLIGAND PHARMACEUTICALS INCORPORATED : Captisol Technology Plays Key Role in the ..
AQ
10/24To Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Co..
DJ
10/24GILEAD SCIENCES : Mexico will not follow FDA in approving Gilead's COVID-19 drug
RE
10/23Stocks mixed; COVID-19 vaccine trials to restart
RE
10/23GILEAD SCIENCES INC : Completion of Acquisition or Disposition of Assets, Other ..
AQ
10/23S&P, Nasdaq close higher as stimulus talks in spotlight
RE
10/23Intel, American Express fall; Mattel, Boston Beer rise
AQ
10/23ASTRAZENECA : Covid-19 Vaccine Trial From AstraZeneca, Oxford Can Resume in U.S...
DJ
10/23ASTRAZENECA : Covid-19 Vaccine Trial From AstraZeneca, Oxford Can Resume in U.S...
DJ
10/23WHO : Nations mulling Gilead's COVID drug should consider trial flop, too
RE
10/23Who chief scientist says u.s. regulatory approval for remdesivir as covid-19..
RE
10/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/23S&P 500, Dow edge higher on hopes of progress in stimulus talks
RE
10/23GILEAD SCIENCES : Anthony Welters Joins Gilead Sciences Board of Directors
AQ
More news
News in other languages on GILEAD SCIENCES, INC.
10/23COUVRE-FEUX, RECONFINEMENT : l'Europe se protège, la France dépasse le million
10/23Aktien New York Schluss: Wenig Bewegung - Gezerre um Hilfspaket
10/23Wall Street sans enthousiasme sur un plan de soutien de l'économie
10/23Aktien Schweiz Schluss: SMI hält sich knapp über 10'000 Punkten
10/23LONDON STOCK EXCHANGE : Londres portée par Barclays et un traitement contre le v..
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Stock Trading Strategies
GILEAD SCIENCES, INC. - 10/07
A medium term support level to take advantage of
BUY
More Stock Trading Analysis
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 78,08 $
Last Close Price 60,79 $
Spread / Highest target 72,7%
Spread / Average Target 28,4%
Spread / Lowest Target -6,23%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.58.33%37 775
BEIGENE, LTD.80.38%27 097
GENMAB A/S49.17%22 988